Cardiff Oncology, Inc. - ROE
CRDF
Price:
$0.81
Market Cap:
$53.16M
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizum...[Read more]
Industry
Biotechnology
IPO Date
2004-07-27
Stock Exchange
NASDAQ
Ticker
CRDF
PE Ratio
[-1.21]
ROE
[-95.50%]
Current Ratio
[3.27]
Dividend Yield
[0%]
Enterprise Value
[45.26M]
Dividend History
The ROE as of July 2026 (TTM) for Cardiff Oncology, Inc. (CRDF) is -95.50%
According to Cardiff Oncology, Inc.’s latest financial reports and current stock price. The company's current ROE is -95.50%. This represents a change of 288.47% compared to the average of -24.58% of the last 4 quarters.
Cardiff Oncology, Inc. (CRDF) Historical ROE (quarterly & annually)
How has CRDF ROE performed in the past?
The mean historical ROE of Cardiff Oncology, Inc. over the last ten years is -125.57%. The current -95.50% ROE has changed -23.95% with respect to the historical average. Over the past ten years (40 quarters), CRDF's ROE was at its highest in in the March 2021 quarter at -4.15%. The ROE was at its lowest in in the June 2017 quarter at -229.18%.
Average
-125.57%
Median
-80.22%
Minimum
-382.83%
Maximum
-15.06%
Cardiff Oncology, Inc. (CRDF) ROE by Quarter and Year
Discovering the peaks and valleys of Cardiff Oncology, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 251.59%
Maximum Annual ROE = -15.06%
Minimum Annual Increase = -93.29%
Minimum Annual ROE = -382.83%
| Year | ROE | Change |
|---|---|---|
| 2025 | -101.02% | 84.44% |
| 2024 | -54.77% | -7.83% |
| 2023 | -59.42% | 63.27% |
| 2022 | -36.40% | 80.64% |
| 2021 | -20.15% | 33.74% |
| 2020 | -15.06% | -93.29% |
| 2019 | -224.50% | 37.53% |
| 2018 | -163.24% | -57.36% |
| 2017 | -382.83% | 93.04% |
| 2016 | -198.32% | 251.59% |
Cardiff Oncology, Inc. (CRDF) Average ROE
How has CRDF ROE performed in the past?
The current ROE of Cardiff Oncology, Inc. (CRDF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-71.74%
5-year avg
-54.35%
10-year avg
-125.57%
Cardiff Oncology, Inc. (CRDF) ROE vs. Peers
How is CRDF’s ROE compared to its peers?
Cardiff Oncology, Inc.’s ROE is greater than Applied Therapeutics, Inc. (-348.18%), greater than Corbus Pharmaceuticals Holdings, Inc. (-70.89%), greater than Elicio Therapeutics, Inc. (-2748.16%), greater than Molecular Partners AG (-66.19%), greater than Forte Biosciences, Inc. (-106.16%), greater than PepGen Inc. (-59.89%), greater than Rani Therapeutics Holdings, Inc. (-245.45%), greater than Milestone Pharmaceuticals Inc. (-339.38%), greater than Cassava Sciences, Inc. (-99.85%), less than Innate Pharma S.A. (593.93%),
| Company | ROE | Market cap |
|---|---|---|
| -348.18% | $14.86M | |
| -70.89% | $165.27M | |
| -2748.16% | $55.10M | |
| -66.19% | $147.42M | |
| -106.16% | $1.57B | |
| -59.89% | $118.28M | |
| -245.45% | $55.12M | |
| -339.38% | $89.32M | |
| -99.85% | $63.77M | |
| 593.93% | $170.90M |
Build a custom stock screener for Cardiff Oncology, Inc. (CRDF) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cardiff Oncology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Cardiff Oncology, Inc. (CRDF) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Cardiff Oncology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Cardiff Oncology, Inc.'s ROE?
How is the ROE calculated for Cardiff Oncology, Inc. (CRDF)?
What is the highest ROE for Cardiff Oncology, Inc. (CRDF)?
What is the 3-year average ROE for Cardiff Oncology, Inc. (CRDF)?
What is the 5-year average ROE for Cardiff Oncology, Inc. (CRDF)?
How does the current ROE for Cardiff Oncology, Inc. (CRDF) compare to its historical average?